Gmeiner, W.H.; Miller, L.D.; Chou, J.W.; Dominijanni, A.; Mutkus, L.; Marini, F.; Ruiz, J.; Dotson, T.; Thomas, K.W.; Parks, G.;
et al. Dysregulated Pyrimidine Biosynthesis Contributes to 5-FU Resistance in SCLC Patient-Derived Organoids but Response to a Novel Polymeric Fluoropyrimidine, CF10. Cancers 2020, 12, 788.
https://doi.org/10.3390/cancers12040788
AMA Style
Gmeiner WH, Miller LD, Chou JW, Dominijanni A, Mutkus L, Marini F, Ruiz J, Dotson T, Thomas KW, Parks G,
et al. Dysregulated Pyrimidine Biosynthesis Contributes to 5-FU Resistance in SCLC Patient-Derived Organoids but Response to a Novel Polymeric Fluoropyrimidine, CF10. Cancers. 2020; 12(4):788.
https://doi.org/10.3390/cancers12040788
Chicago/Turabian Style
Gmeiner, William H., Lance D. Miller, Jeff W. Chou, Anthony Dominijanni, Lysette Mutkus, Frank Marini, Jimmy Ruiz, Travis Dotson, Karl W. Thomas, Graham Parks,
and et al. 2020. "Dysregulated Pyrimidine Biosynthesis Contributes to 5-FU Resistance in SCLC Patient-Derived Organoids but Response to a Novel Polymeric Fluoropyrimidine, CF10" Cancers 12, no. 4: 788.
https://doi.org/10.3390/cancers12040788
APA Style
Gmeiner, W. H., Miller, L. D., Chou, J. W., Dominijanni, A., Mutkus, L., Marini, F., Ruiz, J., Dotson, T., Thomas, K. W., Parks, G., & Bellinger, C. R.
(2020). Dysregulated Pyrimidine Biosynthesis Contributes to 5-FU Resistance in SCLC Patient-Derived Organoids but Response to a Novel Polymeric Fluoropyrimidine, CF10. Cancers, 12(4), 788.
https://doi.org/10.3390/cancers12040788